Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
Anti-VEGF therapy has many limitations that might be resolved by using combination treatment approaches. Here, the authors demonstrate that the dual-targeting of VEGF and PDGF is required for targeting resistant FGF2+ tumors which depend on the recruitment of pericytes on tumor microvessels.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/67e5eca4e69c483cb274470b002be274 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:67e5eca4e69c483cb274470b002be274 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:67e5eca4e69c483cb274470b002be2742021-12-02T16:26:32ZTherapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors10.1038/s41467-020-17525-62041-1723https://doaj.org/article/67e5eca4e69c483cb274470b002be2742020-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-17525-6https://doaj.org/toc/2041-1723Anti-VEGF therapy has many limitations that might be resolved by using combination treatment approaches. Here, the authors demonstrate that the dual-targeting of VEGF and PDGF is required for targeting resistant FGF2+ tumors which depend on the recruitment of pericytes on tumor microvessels.Kayoko HosakaYunlong YangTakahiro SekiQiqiao DuXu JingXingkang HeJieyu WuYin ZhangHiromasa MorikawaMasaki NakamuraMartin ScherzerXiaoting SunYuanfu XuTao ChengXuri LiXialin LiuQi LiYizhi LiuAn HongYuguo ChenYihai CaoNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-15 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Kayoko Hosaka Yunlong Yang Takahiro Seki Qiqiao Du Xu Jing Xingkang He Jieyu Wu Yin Zhang Hiromasa Morikawa Masaki Nakamura Martin Scherzer Xiaoting Sun Yuanfu Xu Tao Cheng Xuri Li Xialin Liu Qi Li Yizhi Liu An Hong Yuguo Chen Yihai Cao Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| description |
Anti-VEGF therapy has many limitations that might be resolved by using combination treatment approaches. Here, the authors demonstrate that the dual-targeting of VEGF and PDGF is required for targeting resistant FGF2+ tumors which depend on the recruitment of pericytes on tumor microvessels. |
| format |
article |
| author |
Kayoko Hosaka Yunlong Yang Takahiro Seki Qiqiao Du Xu Jing Xingkang He Jieyu Wu Yin Zhang Hiromasa Morikawa Masaki Nakamura Martin Scherzer Xiaoting Sun Yuanfu Xu Tao Cheng Xuri Li Xialin Liu Qi Li Yizhi Liu An Hong Yuguo Chen Yihai Cao |
| author_facet |
Kayoko Hosaka Yunlong Yang Takahiro Seki Qiqiao Du Xu Jing Xingkang He Jieyu Wu Yin Zhang Hiromasa Morikawa Masaki Nakamura Martin Scherzer Xiaoting Sun Yuanfu Xu Tao Cheng Xuri Li Xialin Liu Qi Li Yizhi Liu An Hong Yuguo Chen Yihai Cao |
| author_sort |
Kayoko Hosaka |
| title |
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| title_short |
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| title_full |
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| title_fullStr |
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| title_full_unstemmed |
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors |
| title_sort |
therapeutic paradigm of dual targeting vegf and pdgf for effectively treating fgf-2 off-target tumors |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/67e5eca4e69c483cb274470b002be274 |
| work_keys_str_mv |
AT kayokohosaka therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yunlongyang therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT takahiroseki therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT qiqiaodu therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT xujing therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT xingkanghe therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT jieyuwu therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yinzhang therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT hiromasamorikawa therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT masakinakamura therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT martinscherzer therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT xiaotingsun therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yuanfuxu therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT taocheng therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT xurili therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT xialinliu therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT qili therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yizhiliu therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT anhong therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yuguochen therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors AT yihaicao therapeuticparadigmofdualtargetingvegfandpdgfforeffectivelytreatingfgf2offtargettumors |
| _version_ |
1718383994444185600 |